Enclomiphene

trans-clomiphene citrate

Oral SERM (not a peptide) that raises testosterone in secondary hypogonadism while preserving sperm counts.

Unapproved / researchHormones & Fertility

Not FDA-approved. Not FDA-approved (NDA refused 2015). EMA application withdrawn. Compounded in some markets. This page describes research and public discussion; it is not a recommendation to use.

Overview

Enclomiphene is the trans-isomer of clomiphene. Phase 3 trials showed it raised testosterone in overweight men with secondary hypogonadism without suppressing sperm production — unlike exogenous testosterone. The FDA declined approval in 2015 over trial design concerns.

Mechanism of action

Blocks estrogen receptors in the hypothalamus, removing negative feedback and increasing LH/FSH, which stimulates testicular testosterone and sperm production.

Benefits & evidence ratings

Raises serum testosterone into normal range in secondary hypogonadismB Human clinical data

Maintains sperm concentration vs topical testosteroneB Human clinical data

Dosing

Doses show what has been studied or discussed — not guidance. Always follow your prescriber.

Source	Dose	Frequency	Duration	Route
Phase 3 trials B Human clinical data	12.5–25 mg	Once daily	16 weeks	Oral

Clinical trials & studies

Phase 32016
Enclomiphene citrate in secondary hypogonadism — phase 3 (BJU Int)
Raised T and preserved sperm vs topical testosterone.

Safety

Side effects

Headache, hot flushes
Visual disturbances (class effect)
Mood changes
Possible VTE risk (class concern)

Contraindications

Primary testicular failure
Liver disease
History of thromboembolism

Interactions

Testosterone therapy (counterproductive)
Other SERMs/aromatase inhibitors

Long-term safety

Data beyond 1 year are sparse.

Regulatory status

Unapproved / research

Not FDA-approved (NDA refused 2015). EMA application withdrawn. Compounded in some markets.

FAQ

Commonly discussed alongside

Kisspeptin

Listing a combination does not mean it has been studied or is safe.